Ovarian Cancer Canada has announced USD 725,000 in ovarian cancer treatment funding for a natural killer (NK) cell immunotherapy program led by Dr. Jeanette Boudreau at Dalhousie University, with the stated objective of advancing the program to clinical trial readiness. The charitable investment, enabled in part through the River Philip Foundation and donors across Atlantic Canada, targets a cell therapy platform for ovarian cancer and includes development of an AI-powered treatment-planning tool alongside manufacturing infrastructure for clinical-grade NK cell production.
Boudreau, who holds appointments in the Departments of Microbiology and Immunology and Pathology at Dalhousie, has previously reported an association between NK cell activity and longer survival in cancer patients, though the supplied announcement does not cite a specific publication for that prior work. The current funding is intended to translate that biological rationale into a program capable of entering interventional clinical trials, rather than supporting an already-open patient-enrolling study.
Ovarian cancer carries a five-year survival rate of approximately 44% in Canada, where roughly 3,000 new diagnoses occur annually. The disease is frequently detected at later stages due to nonspecific symptoms, limiting the effectiveness of available treatment options. Ovarian Cancer Canada describes itself as the only national charity in Canada dedicated to the disease, and the announcement was timed to coincide with World Ovarian Cancer Day on May 8, 2026.
The program encompasses three components: clinical-enabling development of the NK cell immunotherapy itself, construction of a clinical trials-grade NK cell manufacturing capability in Atlantic Canada, and an AI-based decision-support tool intended to assist clinicians and patients in selecting treatment plans. The manufacturing infrastructure element reflects a regional capacity-building objective, with Ovarian Cancer Canada framing Atlantic Canada as a potential center for clinical-grade NK cell therapy production.